OneMedNet Signs Mediplexus as its 11th Channel Partner, Expanding the Company’s Real World Data Footprint into Korea and the Asia Pacific Region

OneMedNet expands into Asia via Mediplexus, leveraging a 90-million patient data network.

What the company is saying

OneMedNet Corporation is announcing its 11th channel partner agreement, this time with Mediplexus, a subsidiary of C&R Research and a specialist in Real World Data and Real World Evidence. The company frames this as a strategic move to extend its commercial reach into the Asia Pacific region, with Mediplexus appointed as its distributor in Korea. The agreement is structured as an initial one-year engagement, with plans to broaden the collaboration in stages. OneMedNet emphasizes the scale of its iRWD™ network, citing over 90 million patient journeys, 270 million studies, and more than 2,300 healthcare partner sites. The release highlights that its data is sourced directly from providers and de-identified at the source, positioning it as regulatory decision-grade and AI-ready. CEO Aaron Green underscores the expected rapid growth of the Asia Pacific RWE market and the local expertise of Mediplexus and C&R Research as key to unlocking value. The announcement is confident in tone, focusing on future potential and market opportunity rather than immediate financial impact.

What the data suggests

The disclosed figures show that OneMedNet's iRWD™ network currently includes more than 90 million patient journeys, 270 million studies, and over 2,300 healthcare partner sites, establishing a significant operational footprint. The agreement with Mediplexus is the company's 11th channel partnership, marking continued expansion of its distribution network. The partnership is limited to an initial one-year term, with further expansion described as a plan rather than a committed milestone. No revenue, profit, or cash flow figures are disclosed, and there is no evidence of realised commercial activity or customer wins in Asia Pacific as of this announcement. The cited market projections—USD 5.4 billion for the global RWE solutions market in 2025, rising to USD 10.8 billion by 2030—are industry-wide and not specific to OneMedNet's own business. The announcement provides clear operational scale but lacks data on financial performance or direct outcomes from this agreement.

Analysis

The announcement is upbeat, highlighting a new channel partner agreement and the scale of OneMedNet’s data network. The realised facts are the signing of the 11th channel partner agreement and the current size of the iRWD™ network, both supported by specific figures. However, half of the key claims are forward-looking, including plans to broaden the partnership, expand into Asia Pacific, and enable Korean companies to enter the U.S. market—none of which are yet realised or quantified. The language around market growth and partnership expansion is aspirational, with no disclosed financial impact, revenue projections, or profitability metrics. There is no indication of a large capital outlay, and the initial engagement is for one year, suggesting limited immediate risk. The gap between narrative and evidence lies in the emphasis on future opportunities and market size, rather than concrete operational or financial outcomes from this agreement.

Risk flags

• ●The agreement's impact is unquantified, with no disclosed revenue targets, minimum commitments, or operational milestones tied to the Mediplexus partnership. This creates uncertainty about the scale and timing of any financial benefit.
• ●Expansion into Asia Pacific is described aspirationally, with actual commercial activity, customer wins, or regulatory approvals yet to be demonstrated. Execution risk is heightened by the reliance on a new partner and the complexity of cross-border healthcare data markets.
• ●The announcement relies heavily on industry growth projections and the scale of the iRWD™ network, but provides no evidence of how this partnership will convert network size into revenue or market share. The absence of financial metrics makes it difficult to assess the materiality of the agreement.

Bottom line

This announcement signals OneMedNet's intent to expand its data distribution into Korea and the broader Asia Pacific region through a new agreement with Mediplexus. The company demonstrates operational scale with over 90 million patient journeys and 2,300 partner sites, but does not disclose any financial impact, customer wins, or realised revenue from this deal. The partnership is structured as an initial one-year engagement, with future expansion described in general terms. The narrative is credible in terms of network size and industry opportunity, but the lack of concrete financial or operational milestones leaves the business impact unproven. Investors should watch for updates on actual commercial uptake, revenue generation, or expanded scope beyond the first year. The key takeaway is that OneMedNet is positioning itself for growth in a projected $10.8 billion global RWE market, but tangible results from this partnership remain to be seen.

Announcement summary

(NASDAQ:ONMD) OneMedNet Corporation announced its 11th channel partner agreement with Mediplexus, a healthcare data company specializing in Real World Data (RWD) and Real World Evidence (RWE), and a subsidiary of C&R Research. Under the agreement, OneMedNet will supply its U.S.-sourced Real World Data to Mediplexus, which will act as its appointed distributor in Korea. The agreement extends OneMedNet’s commercial reach into the broader Asia Pacific region. The companies plan to broaden the scope of the collaboration in stages following an initial one-year engagement. Mediplexus will offer OneMedNet’s U.S.-sourced healthcare data alongside its own Korean healthcare data, each delivered in a form tailored to the customer’s purpose. This partnership aims to widen opportunities for Korean biopharma, medtech, and medical AI companies to pursue global clinical trials, RWD and RWE research, drug development, and medical AI initiatives. Mediplexus plans to pair OneMedNet’s data with analysis, model validation, and regulatory and market-access support to help Korean medical device and medical AI companies enter the U.S. market. OneMedNet’s iRWD™ network now exceeds 90 million patient journeys, 270 million studies, and more than 2,300 healthcare partner sites. The iRWD™ network delivers multimodal data spanning radiology, cardiology, EEG, and ECG, together with de-identified electronic health records. The data is sourced directly from healthcare providers and de-identified at the source. The agreement comes as the global regulatory environment increasingly moves toward formal acceptance of RWD and RWE. The U.S. FDA and European EMA encourage the use of RWE, and following the adoption of the ICH M14 guideline in 2025, the global RWE solutions market is projected to grow from USD 5.4 billion in 2025 to USD 10.8 billion by 2030. Aaron Green, President & CEO of OneMedNet, stated that Asia Pacific is expected to register the fastest growth in the RWE solutions market, driven by expanding healthcare data infrastructure. He added that the agreement puts OneMedNet’s first-party, direct-from-source multimodal data into the hands of a partner with deep clinical research roots in the region, and that the initial engagement is structured to expand in both scope and geography over time.

Disagree with this article?